Table 4 Baseline clinical characteristics - P.
| Â | Doripenem | Imipenem | Total |
|---|---|---|---|
| Â | ( N = 17) | ( N = 10) | ( N = 27) |
Sex, n (%) | |||
   N | 17 | 10 | 27 |
   Male | 13 (76.5) | 7 (70.0) | 20 (74.1) |
   Female | 4 (23.5) | 3 (30.0) | 7 (25.9) |
Weight (kg) | |||
   N | 17 | 10 | 27 |
   Mean (SD) | 74.0 (17.85) | 68.3 (12.12) | 71.9 (15.96) |
   Median | 75.0 | 64.0 | 72.7 |
   Range | (45; 110) | (52; 90) | (45; 110) |
Height (cm) | |||
   N | 17 | 10 | 27 |
   Mean (SD) | 172.0 (10.11) | 170.8 (7.74) | 171.6 (9.17) |
   Median | 170.0 | 171.0 | 170.0 |
   Range | (156; 190) | (159; 180) | (156; 190) |
Age (Years) | |||
   N | 17 | 10 | 27 |
   Mean (SD) | 57.5 (15.58) | 50.9 (20.32) | 55.1 (17.40) |
   Median | 57.0 | 53.5 | 57.0 |
   Range | (33; 89) | (25; 77) | (25; 89) |
Race, n (%) | |||
   N | 17 | 10 | 27 |
   White | 16 (94.1) | 7 (70.0) | 23 (85.2) |
   Black or African American | 1 (5.9) | 2 (20.0) | 3 (11.1) |
   Asian | 0 | 1 (10.0) | 1 (3.7) |
Region, n (%) | |||
   N | 17 | 10 | 27 |
   Central and South America | 5 (29.4) | 3 (30.0) | 8 (29.6) |
   Eastern Europe and Asia | 5 (29.4) | 4 (40.0) | 9 (33.3) |
   Western Europe, North America, Australia | 7 (41.2) | 3 (30.0) | 10 (37.0) |
APACHE II score group, n (%) | |||
   N | 17 | 10 | 27 |
   ≤15 | 6 (35.3) | 3 (30.0) | 9 (33.3) |
   16 to 19 | 5 (29.4) | 3 (30.0) | 8 (29.6) |
   ≥20 | 6 (35.3) | 4 (40.0) | 10 (37.0) |
CPIS, n (%) | |||
   N | 17 | 10 | 27 |
   <6 | 0 | 1 (10.0) | 1 (3.7) |
   6 to 7 | 10 (58.8) | 8 (80.0) | 18 (66.7) |
   8 to 9 | 5 (29.4) | 1 (10.0) | 6 (22.2) |
   >9 | 2 (11.8) | 0 | 2 (7.4) |
SOFA score | |||
   N | 10 | 4 | 14 |
   Mean (SD) | 5.4 (3.10) | 4.0 (1.41) | 5.0 (2.75) |
   Median | 4.0 | 4.5 | 4.0 |
   Range | (1; 10) | (2; 5) | (1; 10) |
Charlson Comorbidity Index | |||
   N | 17 | 10 | 27 |
   Mean (SD) | 3.0 (2.26) | 2.5 (1.96) | 2.8 (2.13) |
   Median | 3.0 | 3.0 | 3.0 |
   Range | (0; 9) | (0; 5) | (0; 9) |
PaO 2 /FiO 2 , n (%) | |||
   N | 17 | 10 | 27 |
≤250 | 10 (58.8) | 5 (50.0) | 15 (55.6) |
   >250 | 7 (41.2) | 5 (50.0) | 12 (44.4) |
Bacteremia, n (%) | Â | Â | Â |
   N | 17 | 10 | 27 |
   No | 16 (94.1) | 10 (100) | 26 (96.3) |
   Yes | 1 (5.9) | 0 | 1 (3.7) |
Creatinine clearance, n (%) | |||
   N | 17 | 10 | 27 |
   Supra normal(≥150 ml/min) | 5 (29.4) | 4 (40.0) | 9 (33.3) |
   Normal (≥80 to <150 ml/min) | 5 (29.4) | 2 (20.0) | 7 (25.9) |
   Mild renal failure (>50 to <80 ml/min) | 4 (23.5) | 3 (30.0) | 7 (25.9) |
   Moderate renal failure (>30 to ≤50 ml/min) | 2 (11.8) | 1 (10.0) | 3 (11.1) |
   Severe renal failure (≤30 ml/min) | 1 (5.9) | 0 | 1 (3.7) |
Failed antibiotic treatment, n (%) | |||
   N | 11 | 8 | 19 |
   No | 8 (72.7) | 6 (75.0) | 14 (73.7) |
   Yes | 3 (27.3) | 2 (25.0) | 5 (26.3) |
Prior antibacterial therapy usage (hours), n (%) | |||
   N | 17 | 10 | 27 |
   <24 | 4 (23.5) | 0 | 4 (14.8) |
   ≥24 to <48 | 2 (11.8) | 1 (10.0) | 3 (11.1) |
   ≥48 to ≤72 | 1 (5.9) | 0 | 1 (3.7) |
   >72 | 10 (58.8) | 9 (90.0) | 19 (70.4) |
Adjunctive therapy, n (%) | |||
   N | 17 | 10 | 27 |
   No | 7 (41.2) | 6 (60.0) | 13 (48.1) |
   Yes |  |  |  |
≤72 hrs | 8 (47.1) | 3 (30.0) | 11 (40.7) |
   >72 hrs | 2 (11.8) | 1 (10.0) | 3 (11.1) |
Adjunctive aminoglycoside, n (%) | |||
   N | 10 | 4 | 14 |
   No | 4 (40.0) | 2 (50.0) | 6 (42.9) |
   Yes |  |  |  |
≤72 hrs | 5 (50.0) | 2 (50.0) | 7 (50.0) |
   >72 hrs | 1 (10.0) | 0 | 1 (7.1) |
Adjunctive vancomycin/linezolid, n (%) | |||
   N | 10 | 4 | 14 |
   No | 5 (50.0) | 1 (25.0) | 6 (42.9) |
   Yes |  |  |  |
≤72 hrs | 4 (40.0) | 2 (50.0) | 6 (42.9) |
>72 hrs | 1 (10.0) | 1 (25.0) | 2 (14.3) |